Transcatheter Mitral Valve Implantation (TMVI)

The FORTIS transcatheter mitral valve (Edwards Lifesciences, Irvine, CA, USA) is a self-expanding device implanted via a transapical approach that is currently undergoing first-in-man trials. Below is a link to the paper with the latest evidence on the device and a link to the news release.

Bapat et al. 2014 Eurointervention

Edwards News Release

X0000_Edwards_Fortis transcatheter Mitral valve copy_0

About The Author

SHDA is supported by

Recent Tweets


Upcoming Meetings


18octAll Day20Pulmonary Hypertension Society of Australia & New Zealand (PHSANZ) ASM

18octAll Day20European Association for Cardio-Thoracic Surgery (EACTS) 32nd Annual Meeting 2018EACTS 2018

27octAll Day28ECHO Singapore 2018


01novAll Day033rd EACTS European Mechanical Circulatory Support Summit 2018EUMS 2018

08novAll Day11Australian & New Zealand Society of Cardiothoracic Surgeons (ANZSCTS) Annual Scientific Meeting 2018ANZSCTS 2018